Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys.
Here is what one of the more bearish critics had to say. The Rating
Goldman Sachs analyst Salveen Richter. Read More.
Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter s investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in. Read More.